PledPharma brings forward publication date for full year report 2013
February 18, 2014
PledPharma AB Company Announcement PledPharma brings forward publication date for full year report 2013 Stockholm, 2014-02-18 15:25 CET (GLOBE NEWSWIRE) -- PledPharma AB has decided to bring forward the date of publication for the full year report 2013 from 21 February to 19 February 2014. For further information, please contact: Jacques Näsström, CEO +46 737 13 09 79 jacques.nasstrom@pledpharma.se Michaela Gertz, CFO +46 709 26 17 75 michaela.gertz@pledpharma.se About PledPharma PledPharma is a Swedish pharmaceutical company that develops new for prevention of life threatening diseases related to oxidative stress. The initial objective is to develop a drug that reduces the serious side effects associated with chemotherapy. The current market for supportive cancer care is some USD 10 billion. PledPharma also evaluates an existing medicines possibility to reduce the damage that occurs on the heart muscle when a patient suffers from myocardial infarction. In addition to these projects, the company is also evaluating opportunities of using the technology platform in other medical areas where there is a significant unmet medical need in other diseases. PledPharma has the potential to offer patients valuable and unique treatments for serious life-threatening diseases where there is an opportunity for "breakthrough therapy" designation. It also means that the company has the potential to offer shareholders a good return on their investment. PledPharma (STO:PLED) is listed on NASDAQ OMX First North. Erik Penser Bankaktiebolag is the Certified Adviser. For further information, please visit www.pledpharma.se
